Neurodegeneration Focus Cantabio specializes in preclinical stage therapies for Parkinson’s and Alzheimer’s diseases with small molecule pharmacological chaperones and blood-brain barrier–penetrant therapeutic proteins, presenting multiple high-value collaboration and licensing opportunities in CNS drug discovery and delivery.

Early Stage Partnerships With MJFF-backed grants and a history of partnering on tau aggregation and DJ-1 programs, Cantabio offers potential co-development or sponsored research arrangements for target validation, biomarker integration, and joint preclinical programs.

Strategic IP Value The company’s emphasis on commercializing novel therapies from internal R&D and strong IP generation creates openings for strategic licensing of novel small molecules and protein delivery platforms to larger biotech and pharma players seeking CNS franchises.

Funding & Growth Revenue in the low single digits with a small team suggests lean operations and opportunities for strategic investment, grant leveraging, and milestone-driven partnerships to scale preclinical programs without significant upfront risk for partners.

Tech & Data Enablement Utilizing AWS, cloud and web technologies alongside modern frontend stacks indicates readiness for data-intensive collaboration platforms, shared research environments, and multi-institution consortium efforts to accelerate discovery and data integration with potential sales accelerators.